GGrantIndex
← Search

MOLECULAR MECHANISM OF CANCER

$24,940P30FY2016CANIH

University Of Chicago, Chicago IL

Investigators

Linked publications, trials & patents

Paper 39661064Paper 39579248Paper 39438113Paper 39374047Paper 39270007Paper 39141403Paper 39114540Paper 39108474Paper 39071306Paper 39069988Paper 38883758Paper 38881356Paper 38849889Paper 38810242Paper 38771643Paper 38752924Paper 38735044Paper 38716867Paper 38691450Paper 38632339Paper 38561491Paper 38548994Paper 38536082Paper 38533736Paper 38496521Paper 38427437Paper 38421866Paper 38381713Paper 38294692Paper 38294689Paper 38293065Paper 38219706Paper 38213818Paper 38190286Paper 38186960Paper 38175791Paper 38155245Trial NCT02573363Trial NCT02573220Trial NCT02542202Trial NCT02540876Trial NCT02485535Trial NCT02420210Trial NCT02399371Trial NCT02389517Trial NCT02366819Trial NCT02333188Trial NCT02333162Trial NCT02275533Trial NCT02258659Trial NCT02213913Trial NCT02199665Trial NCT02122172Trial NCT02046421Trial NCT02012296Trial NCT01949740Trial NCT01861301Trial NCT01696955Trial NCT01576172Trial NCT01307618Trial NCT01281176Trial NCT01278615Trial NCT01267266Trial NCT01256385Trial NCT01208051Trial NCT01174264Trial NCT01122888Trial NCT01076543Trial NCT01064622Trial NCT00859937Trial NCT00720174Trial NCT00504153Trial NCT00436579Trial NCT00387335Trial NCT00381641Trial NCT00376688Trial NCT00369551Trial NCT00351975Trial NCT00303862Trial NCT00290472Trial NCT00265798Trial NCT00126542Trial NCT00095784Trial NCT00091026Trial NCT00087373Trial NCT00062075Trial NCT00058019Trial NCT00055913Trial NCT00039416Trial NCT00027703Trial NCT00023946Patent 7192711Patent 6870037Patent 6482934Patent 6387619Patent 6043216Patent 5916752Patent 5786344Patent 5698686Patent 5618917

Abstract

The Molecular Mechanisms of Cancer Program (MMC) brings together basic and translational investigators dedicated to the study of cancer through research in cell signaling, molecular biology, systems biology, developmental biology, and chemistry/drug discovery. The Program has refined its membership from 46 to 36 to reflect increased cancer focus. Peer-reviewed funding of $14,681,074 (annual DC), with $5,863,767 from the NCI, has remained steady despite fewer members. Program members are highly-productive, with 416 peer-reviewed publications, including 12% that were intraprogrammatic, and 26% interprogrammatic publications during the past funding period. Moreover, 38% of these articles were published in high impact (impact factor >10) journals. Although our members' interests are varied, several common themes have emerged. Overall, the basic research objectives of our scientists can be divided into the following five themes: 1) to elucidate the molecular mechanisms of tissue-specific and cell type-specific gene expression; 2) to elucidate the cellular mechanisms underlying cell growth/division and cell survival/death; 3) to understand the multi-faceted mechanisms leading to cancer metastases; 4) to use large-scale, high-throughput systems biology approaches and genetic evolutionary approaches to understand cancer biology; and 5) to discover novel developmental pathways relevant to cancer cell signaling. MMC members' fundamental scientific discoveries in these areas are further encouraged by Program 1 leadership to fuel hypothesis-driven clinical and translational cancer research and to contribute to the broader UCCCC initiative of personalized cancer treatment. Significantly, our membership has developed numerous collaborations with clinician-scientists both within the MMC Program and interprogramatically, reflecting the cross-disciplinary and translational nature of our research program. The MMC Program provides support and the structure for these collaborations among the Program's basic cancer biologists, while primarily representing the broad cancer relevant basic science strengths of the University of Chicago (UChicago). Through pilot funding, quarterly membership meetings, a seminar series, an annual retreat, and a strong basic science training program in cancer biology, the MMC Program is poised to continue its successful in-depth and basic research focus on cancer biology, while nurturing collaborative science that will enhance the clinical care of patients at risk or with cancer.

View original record on NIH RePORTER →